Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke
- 1 July 2005
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (7) , 1447-1451
- https://doi.org/10.1161/01.str.0000170647.42126.a8
Abstract
Background and Purpose— Previous reports suggest that women achieve better outcome than men after intravenous thrombolysis for ischemic stroke. Coagulation and fibrinolysis differ between sexes. These findings prompted us to investigate possible gender differences in arterial recanalization after intravenous tissue plasminogen activator (IV tPA). Methods— We identified 100 consecutive patients who presented with acute ischemic stroke and received IV tPA within 6 hours of onset. Only patients with large artery anterior circulation strokes, as determined by MRI/MRA or CT/CTA before treatment, who had follow-up vascular study within 72 hour after treatment were included. We compared demographics, clinical features, admission medications, symptom-to-needle and treatment-to-repeat vascular imaging times, baseline National Institutes of Health Stroke Severity score, radiological and laboratory data, stroke mechanism, and outcome between the sexes. Results— 39 patients met all inclusion/exclusion criteria (22 men and 17 women). The recanalization rate was significantly higher in women (94% versus 59%; P =0.02). This difference remained statistically significant after excluding patients whose strokes were attributed to internal carotid artery occlusive lesions, and when the analysis was limited to those treated within 3 hours of stroke onset. All other confounding variables did not differ significantly between the sexes. Conclusions— In our cohort, vascular occlusive lesions were more likely to recanalize in women than men in response to IV tPA. These preliminary findings need to be validated in larger prospective studies.Keywords
This publication has 24 references indexed in Scilit:
- Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic StrokeStroke, 2005
- Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal WomenCirculation, 2004
- Differences in Clot Preparation Determine Outcome of Recombinant Tissue Plasminogen Activator Treatment in Experimental Thromboembolic StrokeStroke, 2003
- Baseline Magnetic Resonance Imaging Parameters and Stroke Outcome in Patients Treated by Intravenous Tissue Plasminogen ActivatorStroke, 2003
- Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 HoursStroke, 2002
- Early Dramatic Recovery During Intravenous Tissue Plasminogen Activator InfusionStroke, 2002
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Role of new antiplatelet agents as adjunctive therapies in thrombolysisThe American Journal of Cardiology, 1991
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985